Investigational Sanofi drug shows improvements in MS patients

CAMBRIDGE, Mass. — More than three-quarters of patients with multiple sclerosis using a drug made by Sanofi subsidiary Genzyme did not experience disease relapse for two years, according to results of a late-stage clinical trial revealed over the weekend.



The drug maker announced Saturday results of the "CARE-MS I" trial, the first of two phase-3 clinical trials comparing the investigational drug Lemtrada (alemtuzumab) with Pfizer's and EMD Serono's Rebif (interferon beta-1a) in patients with relapsing-remitting MS.



Data from the trial showed that after two years, 78% of patients taking Lemtrada remained relapse-free, compared with 59% of those taking Rebif.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.